Literature DB >> 21084444

The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle.

Carlo Serra1, Shalender Bhasin, Frances Tangherlini, Elisabeth R Barton, Michelle Ganno, Anqi Zhang, Janet Shansky, Herman H Vandenburgh, Thomas G Travison, Ravi Jasuja, Carl Morris.   

Abstract

Testosterone (T) supplementation increases skeletal muscle mass, circulating GH, IGF-I, and im IGF-I expression, but the role of GH and IGF-I in mediating T's effects on the skeletal muscle remains poorly understood. Here, we show that T administration increased body weight and the mass of the androgen-dependent levator ani muscle in hypophysectomized as well as castrated plus hypophysectomized adult male rats. T stimulated the proliferation of primary human skeletal muscle cells (hSKMCs) in vitro, an effect blocked by transfecting hSKMCs with small interference RNA targeting human IGF-I receptor (IGF-IR). In differentiation conditions, T promoted the fusion of hSKMCs into larger myotubes, an effect attenuated by small interference RNA targeting human IGF-IR. Notably, MKR mice, which express a dominant negative form of the IGF-IR in skeletal muscle fibers, treated with a GnRH antagonist (acyline) to suppress endogenous T, responded to T administration by an attenuated increase in the levator ani muscle mass. In conclusion, circulating GH and IGF-I are not essential for mediating T's effects on an androgen-responsive skeletal muscle. IGF-I signaling plays an important role in mediating T's effects on skeletal muscle progenitor cell growth and differentiation in vitro. However, IGF-IR signaling in skeletal muscle fibers does not appear to be obligatory for mediating the anabolic effects of T on the mass of androgen-responsive skeletal muscles in mice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21084444      PMCID: PMC3033058          DOI: 10.1210/en.2010-0802

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  51 in total

1.  Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle.

Authors:  Ana M Fernández; Joëlle Dupont; Roger P Farrar; Sukho Lee; Bethel Stannard; Derek Le Roith
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

2.  Androgen receptor enhances myogenin expression and accelerates differentiation.

Authors:  Dong Kun Lee
Journal:  Biochem Biophys Res Commun       Date:  2002-06-07       Impact factor: 3.575

3.  Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.

Authors:  C Rommel; S C Bodine; B A Clarke; R Rossman; L Nunez; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

4.  Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone.

Authors:  Michael I Lewis; Gail D Horvitz; David R Clemmons; Mario Fournier
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-02       Impact factor: 4.310

5.  Testosterone administration to older men improves muscle function: molecular and physiological mechanisms.

Authors:  Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

6.  IGF-1 receptor mediates differentiation of primary cultures of mouse skeletal myoblasts.

Authors:  C D Galvin; O Hardiman; C M Nolan
Journal:  Mol Cell Endocrinol       Date:  2003-02-28       Impact factor: 4.102

7.  Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation.

Authors:  Shi Yu Yang; Geoffrey Goldspink
Journal:  FEBS Lett       Date:  2002-07-03       Impact factor: 4.124

8.  Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage.

Authors:  Maria Hill; Geoffrey Goldspink
Journal:  J Physiol       Date:  2003-04-11       Impact factor: 5.182

9.  Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise.

Authors:  M Hameed; R W Orrell; M Cobbold; G Goldspink; S D R Harridge
Journal:  J Physiol       Date:  2002-12-20       Impact factor: 5.182

10.  Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy.

Authors:  Indrani Sinha-Hikim; Jorge Artaza; Linda Woodhouse; Nestor Gonzalez-Cadavid; Atam B Singh; Martin I Lee; Thomas W Storer; Richard Casaburi; Ruoquing Shen; Shalender Bhasin
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-07       Impact factor: 4.310

View more
  31 in total

Review 1.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking β-catenin nuclear translocation and cross-talk with TGF-β signaling in keratinocytes.

Authors:  Gianluca Toraldo; Shalender Bhasin; Mena Bakhit; Wen Guo; Carlo Serra; Joshua D Safer; Jag Bhawan; Ravi Jasuja
Journal:  Wound Repair Regen       Date:  2012 Jan-Feb       Impact factor: 3.617

Review 4.  The therapeutic potential of IGF-I in skeletal muscle repair.

Authors:  Yao-Hua Song; Jenny L Song; Patrice Delafontaine; Michael P Godard
Journal:  Trends Endocrinol Metab       Date:  2013-04-27       Impact factor: 12.015

Review 5.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

6.  Androgenic and estrogenic regulation of Atrogin-1, MuRF1 and myostatin expression in different muscle types of male mice.

Authors:  H De Naeyer; S Lamon; A P Russell; I Everaert; A De Spaey; B Vanheel; Y Taes; W Derave
Journal:  Eur J Appl Physiol       Date:  2014-01-05       Impact factor: 3.078

Review 7.  Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle.

Authors:  Robert A Frost; Charles H Lang
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-10       Impact factor: 4.741

8.  The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.

Authors:  Shehzad Basaria; Lauren Collins; E Lichar Dillon; Katie Orwoll; Thomas W Storer; Renee Miciek; Jagadish Ulloor; Anqi Zhang; Richard Eder; Heather Zientek; Gilad Gordon; Syed Kazmi; Melinda Sheffield-Moore; Shalender Bhasin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-28       Impact factor: 6.053

9.  Testosterone responses to standardized short-term sub-maximal and maximal endurance exercises: issues on the dynamic adaptive role of the hypothalamic-pituitary-testicular axis.

Authors:  P Sgrò; F Romanelli; F Felici; M Sansone; S Bianchini; C F Buzzachera; C Baldari; L Guidetti; F Pigozzi; A Lenzi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

10.  Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.

Authors:  Caroline Barbé; Stéphanie Kalista; Audrey Loumaye; Olli Ritvos; Pascale Lause; Benjamin Ferracin; Jean-Paul Thissen
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-28       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.